Company Overview and News
LOCAL DEBT watcher Philippine Ratings Services Corp. (PhilRatings) assigned the highest credit rating for Ayala Land, Inc.’s (ALI) proposed issuance of fixed rate bonds worth P8 billion.
AYAAY ALI AYAAF
THE MAIN INDEX barely moved on Monday as investors stayed on the sidelines following the typhoon that ravaged some parts of the country over the weekend, alongside prevailing fears over the trade war between the United States and China.
PSKXF ASFOF FOOD AYAAY UVRBY SMPH SPHXY URC PHSXY PSE SPHXF SPHZF ALI UVRBF AYAAF
Overseas Filipinos have become purveyors of a new ultra-modern lifestyle that is rapidly being introduced to every corner of the Philippines, says one observer.
FVSMF AYAAY FLI ALI AYAAF
The local stock barometer slid below the crucial 7,800 mark on Wednesday as investors were spooked by higher-than-expected Philippine August inflation alongside emerging market contagion jitters.
SVTMF PSKXF GTMEY AYAAY SM GLOPP GLO SMIVY PHSXY GTMEF PSE GLOPA ALI AYAAF
The local stock barometer gained on Tuesday as local investors made up for sluggish foreign investor appetite.
SVTMF SMCP1 BDOUY SM MRAIF BDOUF SMGBF SMIVY SMC PHSXY PSE AYAAF PSKXF AYAAY SMGBY BDO SMC2B SMC2A SMC2D IDC SMC2C SMC2F SMC2E ALI MRC
D.M. WENCESLAO & Associates, Inc. (DMW) is limiting its exposure to Philippine Offshore Gaming Operators (POGOs) to around 30% of the company’s tenant mix in the Bay Area.
AYAAY ALI AYAAF
The benchmark Philippine Stock Exchange index closed in positive territory Thursday even as regional equities saw mixed results on lingering trade tensions between the United States and China.
ICT GTCAP GTCXY SVTMF BDOUY SM ICTEF SECB BDOUF SMIVY MPCFF PHSXY PSE SPHXF SPHZF AYAAF PSKXF MPCIY AYAAY SMPH BDO MPI SPHXY SYBJF ALI
The local stock barometer yesterday rallied to the 7,800 mark, outperforming regional markets, as foreign fund managers picked up large-cap stocks.
PSKXF SMCP1 AYAAY SMGBY SMGBF SMC2B SMC2A SMC SMC2D SMC2C SMC2F SMC2E PHSXY PSE ALI AYAAF
More property developers are developing residential condominiums near educational institutions, as they aim to take advantage of the lack of players in the area.
AYAAY ALI AYAAF
11h - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
11h - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
13h - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET